Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Matt Hrapchak"'
Autor:
Maxim Cheveliakov, Matt Hrapchak, Carl A. Busacca, Jonathan T. Reeves, Bachir Latli, Chris H. Senanayake, Maurice A. Marsini
Publikováno v:
Journal of Labelled Compounds and Radiopharmaceuticals. 61:764-772
1-(4-Fluorophenyl)-1H-pyrazolo[3,4-c]pyridine-4-carboxylic acid (2-methanesulfonyl-pyridin-4-ylmethyl)-amide (1) and its analogs (2) and (3) are potent CCR1 antagonists intended for the treatment of rheumatoid arthritis. The detailed syntheses of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::872f6b27cecdba3a37ccf34d93d383ac
https://doi.org/10.1002/jlcr.3635
https://doi.org/10.1002/jlcr.3635
Autor:
Heewon Lee, Zhibin Li, Carl A. Busacca, Nelu Grinberg, Michael Dipl Chem Dr Stiasni, Chris H. Senanayake, Bachir Latli, Matt Hrapchak
Publikováno v:
Journal of Labelled Compounds and Radiopharmaceuticals. 59:557-564
Hyosine butyl bromide, the active ingredient in Buscopan, is an anticholinergic and antimuscarinic drug used to treat pain and discomfort caused by abdominal cramps. A straightforward synthesis of carbon-14– and deuterium-labeled Buscopan was devel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a4331725c689a3a042f3893d6a8136d8
https://doi.org/10.1002/jlcr.3463
https://doi.org/10.1002/jlcr.3463
Autor:
Ralf Kiesling, Stefan Aßfalg, Chris H. Senanayake, Nina C. Gonnella, Max Chevliakov, Matt Hrapchak, Bachir Latli, Carl A. Busacca, Scot Campbell
Publikováno v:
Journal of Labelled Compounds and Radiopharmaceuticals. 59:648-656
Dabigatran etexilate or pradaxa, a novel oral anticoagulant, is a reversible, competitive, direct thrombin inhibitor. It is used to prevent strokes in patients with atrial fibrillation and the formation of blood clots in the veins (deep venous thromb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3bf4c3c455cec18b6f0ad31f71611f53
https://doi.org/10.1002/jlcr.3402
https://doi.org/10.1002/jlcr.3402
Publikováno v:
Journal of Labelled Compounds and Radiopharmaceuticals. 59:300-304
3-Amino-4-(1,1-difluoro-propyl)-6-(4-methanesulfonyl-piperidin-1-yl)-thieno[2,3-b]pyridine-2-carboxylic acid amide (1) is a potent IκB Kinase-β (IKK-β) inhibitor. The efficient preparations of this compound labeled with carbon-14 and deuterium are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ba55801deb61340f589f32caff0dcac5
https://doi.org/10.1002/jlcr.3398
https://doi.org/10.1002/jlcr.3398
Autor:
Josh Horan, Matt Hrapchak, Jon C. Lorenz, Carl A. Busacca, Bachir Latli, Guisheng Li, Chris H. Senanayake
Publikováno v:
Journal of labelled compoundsradiopharmaceuticals. 62(2)
The drug candidates (2) and (3) are highly potent LFA-1 inhibitors. They were efficiently prepared labeled with carbon-14 using a palladium-catalyzed carboxylation of an iodo-precursor (5) and sodium formate-14 C to afford acid [14 C]-(6), which was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a05698be0a3e60a7502e225397bf9b4c
https://pubmed.ncbi.nlm.nih.gov/30466143
https://pubmed.ncbi.nlm.nih.gov/30466143
Autor:
Carl B. Busacca, Zhulin Tan, Bachir Latli, Jinhua J. Song, Matt Hrapchak, Jonathan T. Reeves, Chris H. Senanayake
Publikováno v:
Journal of Labelled Compounds and Radiopharmaceuticals. 58:445-452
Two potent glucocorticoid receptor agonists were prepared labeled with carbon-14 and with stable isotopes to perform drug metabolism, pharmacokinetics, and bioanalytical studies. Carbon-14 labeled (1) was obtained from an enantiopure alkyne (5) via a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5dcc76569ba93a6edc64ec96d0e952a3
https://doi.org/10.1002/jlcr.3349
https://doi.org/10.1002/jlcr.3349
Publikováno v:
Journal of Labelled Compounds and Radiopharmaceuticals. 58:390-394
2-[4-(3-{(1R)-1-[4-(2-Aminopyrimidin-5-yl)phenyl]-1-cyclopropylethyl}-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl]-N,N-dimethylacetamide (1), is a novel and selective five-lipoxygenase activity protein (FLAP) inhibitor with excellent pharmacokinetics prope
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7f96645b1526de55faf19433740907fc
https://doi.org/10.1002/jlcr.3319
https://doi.org/10.1002/jlcr.3319
Autor:
Chris H. Senanayake, Carl A. Busacca, Scot Campbell, Bachir Latli, Matt Hrapchak, Maxim Chevliakov, Guisheng Li
Publikováno v:
Journal of Labelled Compounds and Radiopharmaceuticals. 58:250-260
Deleobuvir, (2E)-3-(2-{1-[2-(5-bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1H-indole-6-carboxamido]cyclobutyl}-1-methyl-1H-benzimidazol-6-yl)prop-2-enoic acid (1), is a non-nucleoside, potent, and selective inhibitor of hepatitis C virus NS5B polymer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4a53a24bb2928cb5b527a9bef4422e79
https://doi.org/10.1002/jlcr.3294
https://doi.org/10.1002/jlcr.3294
Autor:
Matt Hrapchak, Jolaine Savoie, Yongda Zhang, Chris H. Senanayake, Carl A. Busacca, Bachir Latli
Publikováno v:
Journal of labelled compoundsradiopharmaceuticals. 60(9)
(S)-6-(2-Hydroxy-2-methylpropyl)-3-((S)-1-(4-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one (1) and (4aR,9aS)-1-(1H-benzo[d]midazole-5-carbonyl)-2,3,4,4a,9,9a-hexahydro-1-H-indeno[2,1-b]pyridine-6-carbonitrile hydro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97de8773a6b85a035c9f67ef274d5e73
https://pubmed.ncbi.nlm.nih.gov/29405358
https://pubmed.ncbi.nlm.nih.gov/29405358
Autor:
Jinhua J. Song, Bachir Latli, Matt Hrapchak, Xiao-Jun Wang, Chris H. Senanayake, Heewon Lee, Scot Campbell
Publikováno v:
Journal of Labelled Compounds and Radiopharmaceuticals. 57:687-694
Empagliflozin, (2S,3R,4R,5S,6R)-2-[4-chloro-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol was recently approved by the FDA for the treatment of chronic type 2 diabetes mellitus. Herein, we report the synthesis of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::98880dbd1355b82f73ba6074bf7f1779
https://doi.org/10.1002/jlcr.3240
https://doi.org/10.1002/jlcr.3240